LinkedIn Profile

Access Eiger BioPharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:eigr 248168 Apr 14th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 13th, 2024 10:58PM Apr 14th, 2024 10:56AM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 13th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 12th, 2024 10:49PM Apr 13th, 2024 11:24AM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 12th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 11th, 2024 10:54PM Apr 12th, 2024 08:19AM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 11th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 10th, 2024 11:27PM Apr 11th, 2024 11:04AM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 10th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 9th, 2024 10:57PM Apr 10th, 2024 05:12PM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 9th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 8th, 2024 11:08PM Apr 9th, 2024 09:53AM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 8th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 34.00 Open Apr 7th, 2024 11:33PM Apr 8th, 2024 06:51PM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 7th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 35.00 Open Apr 6th, 2024 11:04PM Apr 6th, 2024 11:04PM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 6th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 35.00 Open Apr 5th, 2024 11:04PM Apr 5th, 2024 11:04PM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:eigr 248168 Apr 5th, 2024 12:00AM Eiger BioPharmaceuticals 4.6K 37.00 Open Apr 4th, 2024 11:31PM Apr 4th, 2024 11:31PM Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases. Eiger's lead product candidate, avexitide, is a well characterized, first-in-class GLP-1 antagonist for the treatment of post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). Avexitide is the only drug in development for PBH with Breakthrough Therapy designation from the FDA. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com. For our social media and community guidelines, including information on how to report adverse events, please visit www.eigerbio.com/social-media-guidelines/ Open Open US Eiger BioPharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.